
ENDRA Life Sciences NDRA
$ 3.58
-7.97%
ENDRA Life Sciences Total Non Current Liabilities | NDRA
Annual Total Non Current Liabilities ENDRA Life Sciences
| 2026 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 846 K | 843 K | 1.29 M | 192 K | 366 K | 547 K | 609 K | 343 K | - | - | - | 1 | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.29 M | 1 | 559 K |
Quarterly Total Non Current Liabilities ENDRA Life Sciences
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 886 K | 846 K | 816 K | 843 K | 992 K | 758 K | 852 K | 1.29 M | 960 K | 98.4 K | 146 K | 192 K | 237 K | 281 K | 324 K | 366 K | 434 K | 473 K | 510 K | 547 K | 581 K | 615 K | 281 K | 609 K | 628 K | 645 K | 326 K | 343 K | 359 K | 343 K | 343 K | - | 681 K | 354 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.29 M | 98.4 K | 544 K |
Total Non Current Liabilities of other stocks in the Diagnostics research industry
| Issuer | Total Non Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Enzo Biochem
ENZ
|
4.6 M | - | -8.98 % | $ 14.8 K | ||
|
Chembio Diagnostics
CEMI
|
24.8 M | - | 0.22 % | $ 16.8 M | ||
|
Meridian Bioscience
VIVO
|
37.1 M | - | - | $ 1.49 B | ||
|
Heska Corporation
HSKA
|
57.9 M | - | - | $ 1.31 B | ||
|
Accelerate Diagnostics
AXDX
|
134 M | - | -61.36 % | $ 2.46 M | ||
|
T2 Biosystems
TTOO
|
6.68 M | - | -39.35 % | $ 313 K | ||
|
Syneos Health
SYNH
|
2.97 B | - | - | $ 4.46 B | ||
|
Biocept
BIOC
|
11.3 M | - | -13.05 % | $ 7.29 M | ||
|
Invitae Corporation
NVTA
|
320 M | - | - | $ 21.2 M | ||
|
Quotient Limited
QTNT
|
201 M | - | -11.32 % | $ 1.1 M | ||
|
Brainsway Ltd.
BWAY
|
16.7 M | $ 8.53 | -2.29 % | $ 290 M | ||
|
Burning Rock Biotech Limited
BNR
|
38.1 M | $ 13.46 | 1.05 % | $ 142 M | ||
|
Medpace Holdings
MEDP
|
73.8 M | $ 609.81 | -3.81 % | $ 17.6 B | ||
|
DermTech
DMTK
|
865 K | - | -11.32 % | $ 2.94 M | ||
|
Surmodics
SRDX
|
17.1 M | - | - | $ 608 M | ||
|
RadNet
RDNT
|
1.82 B | $ 69.77 | 0.37 % | $ 5.25 B | ||
|
Akumin
AKU
|
527 M | - | -17.87 % | $ 25.9 M | ||
|
Psychemedics Corporation
PMD
|
4.88 M | - | -1.84 % | $ 15.3 M | ||
|
IDEXX Laboratories
IDXX
|
597 M | $ 675.24 | -2.09 % | $ 54.3 B | ||
|
Motus GI Holdings
MOTS
|
2.16 M | - | -34.28 % | $ 263 K | ||
|
Biodesix
BDSX
|
72.5 M | $ 7.55 | -9.1 % | $ 57 M | ||
|
HTG Molecular Diagnostics
HTGM
|
4.1 M | - | -20.0 % | $ 1.06 M | ||
|
Agilent Technologies
A
|
3.29 B | $ 169.82 | -3.21 % | $ 48.2 B | ||
|
Charles River Laboratories International
CRL
|
2.8 B | $ 314.38 | -4.13 % | $ 15.6 B | ||
|
Quest Diagnostics Incorporated
DGX
|
5.17 B | $ 257.78 | -0.4 % | $ 28.6 B | ||
|
Danaher Corporation
DHR
|
26.9 B | $ 220.3 | -3.19 % | $ 157 B | ||
|
DexCom
DXCM
|
1.45 B | $ 79.02 | -1.46 % | $ 30.8 B | ||
|
Anixa Biosciences
ANIX
|
4.17 M | $ 2.44 | -6.15 % | $ 79.2 K | ||
|
Celcuity
CELC
|
322 M | $ 53.32 | -5.31 % | $ 2.49 B | ||
|
Guardant Health
GH
|
1.81 B | $ 145.9 | 0.21 % | $ 18.3 B | ||
|
BioNano Genomics
BNGO
|
6.22 M | $ 0.82 | -7.56 % | $ 4.46 M | ||
|
Bioventus
BVS
|
295 M | $ 9.89 | -0.65 % | $ 659 M | ||
|
IQVIA Holdings
IQV
|
15 B | $ 245.67 | -1.92 % | $ 42.2 B | ||
|
Laboratory Corporation of America Holdings
LH
|
6.93 B | $ 367.68 | -0.44 % | $ 30.6 B | ||
|
Castle Biosciences
CSTL
|
39 M | $ 32.69 | -2.14 % | $ 948 M | ||
|
Mettler-Toledo International
MTD
|
2.54 B | $ 1 667.59 | -2.3 % | $ 34.4 B | ||
|
Illumina
ILMN
|
2.04 B | $ 192.79 | -3.92 % | $ 29.9 B | ||
|
Natera
NTRA
|
245 M | $ 273.11 | -5.8 % | $ 37.3 B | ||
|
Koninklijke Philips N.V.
PHG
|
8.45 B | $ 28.63 | -2.22 % | $ 27.1 B | ||
|
Fulgent Genetics
FLGT
|
21.8 M | $ 24.03 | -3.03 % | $ 740 M | ||
|
CareDx, Inc
CDNA
|
20.3 M | $ 69.9 | -2.81 % | $ 3.72 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
7.74 M | - | - | $ 562 M | ||
|
Biomerica
BMRA
|
1.57 M | $ 1.09 | -0.46 % | $ 3.18 M | ||
|
Interpace Biosciences
IDXG
|
6.37 M | $ 4.4 | -4.35 % | $ 19.5 M | ||
|
Lantheus Holdings
LNTH
|
804 M | $ 102.12 | 0.01 % | $ 6.89 B | ||
|
Senseonics Holdings
SENS
|
40.9 M | $ 8.03 | -9.88 % | $ 335 M | ||
|
Sotera Health Company
SHC
|
2.41 B | $ 15.92 | -1.82 % | $ 4.52 B | ||
|
Fluidigm Corporation
FLDM
|
131 M | - | 1.08 % | $ 308 M | ||
|
ICON Public Limited Company
ICLR
|
3.88 B | $ 186.79 | -1.88 % | $ 14.6 B |